INT78896

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 2.43
Pain Relevance 1.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (CCL5) aging (CCL5) extracellular region (CCL5)
cell-cell signaling (CCL5) cytoplasm (CCL5)
Anatomy Link Frequency
T cells 4
synovial fluid 2
AMs 2
epithelial cells 2
CCL5 (Homo sapiens)
Pain Link Frequency Relevance Heat
dexamethasone 11 99.70 Very High Very High Very High
cytokine 50 98.64 Very High Very High Very High
Inflammation 224 98.00 Very High Very High Very High
chemokine 192 96.72 Very High Very High Very High
cINOD 11 89.28 High High
Arthritis 150 73.64 Quite High
methotrexate 42 53.60 Quite High
Rheumatism 3 36.44 Quite Low
Glutamate 2 8.00 Low Low
rheumatoid arthritis 28 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
INFLAMMATION 243 98.00 Very High Very High Very High
Sinusitis 1 94.44 High High
Common Cold 3 92.32 High High
Adhesions 14 83.40 Quite High
Asthma 42 76.28 Quite High
Hypersensitivity 4 75.88 Quite High
Injury 5 75.00 Quite High
Influenza Virus Infection 3 74.16 Quite High
Pneumonia 2 73.88 Quite High
Juvenile Chronic Polyarthritis 120 73.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As expected, PB T cells showed low levels of secreted CCL5 without stimulation, and responded to stimulation by an increased release of CCL5 that was partially inhibited (33% inhibition compared to maximal release) by cyclohexamide (Figure 4).
Negative_regulation (inhibited) of Localization (release) of CCL5 in T cells
1) Confidence 0.57 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526593 Disease Relevance 0.06 Pain Relevance 0.13
In parallel with the cell preparations, small volumes of PB or SF were used to prepare cell-free fluid (plasma or synovial fluid, respectively) using a protocol to minimise platelet release to prevent release of CCL5 from platelets [33].
Negative_regulation (prevent) of Localization (release) of CCL5 in synovial fluid
2) Confidence 0.42 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526593 Disease Relevance 0 Pain Relevance 0.05
This correlates with recent reports that CCL5 secretion from memory and effector CD8+ T cells is from stored granules, thought to be distinct from lysosomal secretory granules, and that this secretion of CCL5 is resistant to ER and Golgi blockade [36,37].
Negative_regulation (resistant) of Localization (secretion) of CCL5 in T cells
3) Confidence 0.42 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526593 Disease Relevance 0.14 Pain Relevance 0.15
In the same conditions, dexamethasone significantly inhibited the release both of TNF-alpha and RANTES by AMs, mainly acting at the mRNA level, but had no effect on ICAM-1 expression.
Negative_regulation (inhibited) of Localization (release) of RANTES in AMs associated with dexamethasone
4) Confidence 0.40 Published 1998 Journal Transpl. Immunol. Section Abstract Doc Link 9848225 Disease Relevance 0.37 Pain Relevance 0.34
TNF-alpha production, but not RANTES release (measured by ELISA), was significantly inhibited. mRNA studies, by means of polymerase chain reaction amplification of complementary deoxyribonucleic acids (RT-PCR), showed no significant modification of mRNA levels, suggesting that fusafungine acts mainly at a post-transcriptional level.
Negative_regulation (inhibited) of Localization (release) of RANTES
5) Confidence 0.35 Published 1998 Journal Transpl. Immunol. Section Abstract Doc Link 9848225 Disease Relevance 0.27 Pain Relevance 0.28
The Th2-type cytokine IL-10, however, failed to attenuate RANTES mRNA expression but did inhibit secretion of RANTES induced by a combination of IFN-?
Negative_regulation (inhibit) of Localization (secretion) of RANTES associated with cytokine
6) Confidence 0.13 Published 2002 Journal Respir Res Section Body Doc Link PMC64809 Disease Relevance 0.34 Pain Relevance 0.19
The results showed that 10 microg/mL DHMEQ potently inhibited ICAM-1 production (by 50%), as well as the release of MCP-1 (to 25% of control), RANTES (to 5% of control) and IL-8 (to 2% of control).
Negative_regulation (inhibited) of Localization (release) of RANTES
7) Confidence 0.03 Published 2010 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 20337659 Disease Relevance 0.51 Pain Relevance 0.18
A. paniculata extract inhibits secretion of RANTES, a potent chemoattractant exacerbating bronchial inflammation as a result of H1N1-infected human bronchial epithelial cells [86].
Negative_regulation (inhibits) of Localization (secretion) of RANTES in epithelial cells associated with inflammation
8) Confidence 0.02 Published 2010 Journal Chin Med Section Body Doc Link PMC2881933 Disease Relevance 0.75 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox